Amended Current Report Filing (8-k/a)
August 10 2020 - 5:00AM
Edgar (US Regulatory)
MERIDIAN BIOSCIENCE INC true 0000794172 0000794172 2020-08-07 2020-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K/A
Amendment No. 1
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 7, 2020
MERIDIAN BIOSCIENCE, INC.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Ohio
|
|
0-14902
|
|
31-0888197
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
3471 River Hills Drive, Cincinnati, Ohio
|
|
45244
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code (513) 271-3700
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, no par value
|
|
VIVO
|
|
NASDAQ Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17CFR §240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Item 2.02.
|
Results of Operations and Financial Condition.
|
On August 7, 2020, Meridian Bioscience, Inc. (“Meridian” or the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) under Items 2.02 and 7.01 in connection with the issuance of a press release (the “Release”) announcing results for the third quarter ended June 30, 2020. The Original 8-K included a copy of a presentation related to the Company’s August 7, 2020 conference call (the “Presentation”) and the Release as exhibits. Meridian is filing this Amendment No. 1 on Form 8-K for the purpose of correcting a typographical error included in the Release and Presentation. The references to the diluted share count of 42.2M shares on page 2 of the Release and on slide 7 of the Presentation are replaced by 43.2M shares.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
MERIDIAN BIOSCIENCE, INC.
|
|
|
|
|
Date: August 7, 2020
|
|
|
|
By:
|
|
/s/ Bryan T. Baldasare
|
|
|
|
|
|
|
Executive Vice President and Chief Financial Officer
|
|
|
|
|
|
|
(Principal Financial and Accounting Officer)
|
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Meridian Bioscience Inc (NASDAQ): 0 recent articles
More Meridian Bioscience Inc News Articles